Iron metabolism and iron chelation in sickle cell disease

Acta Haematologica

Volumn 122, Issue 2-3, 2009, Pages 174-183

  Walter, Patrick B ^a   Harmatz, Paul ^a   Vichinsky, Elliott ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Cytokines; Iron metabolism; Iron trafficking; Non transferrin bound iron; Pediatric hemoglobinopathy; Sickle cell disease; Transfusion

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEPCIDIN; TRANSFERRIN;

ARTHRALGIA; BLOOD TRANSFUSION; CHELATION THERAPY; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HEMOGLOBINOPATHY; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIVER CELL; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RETICULOENDOTHELIAL SYSTEM; REVIEW; SICKLE CELL ANEMIA; TRANSFUSION;

ANEMIA, SICKLE CELL; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 70450219830     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000243802     Document Type: Review

References (87)

1. Konotey-Ahulu FID: Effect of environment on sickle cell disease in West Africa: Epidemiologic and clinical considerations; in Abramson H, Bertles JF, Wethers DL (eds): Sickle Cell Disease, Diagnosis, Management, Education and Research. St. Louis, Mosby, 1973, p 20.
2. Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487.
3. Repka T, Hebbel RP: Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood 1991; 78: 2753-2758.
4. Aslan M, Freeman BA: Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease - mechanisms and consequences. Cell Mol Biol (Noisy-le-grand) 2004; 50: 95-105.
5. Wood KC, Hebbel RP, Granger DN: Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 2005; 19: 989-991.
6. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P: Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135: 254-263.
7. Hebbel RP: Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med 2000; 342: 1910-1912.
8. Rechavi G, Rivella S: Regulation of iron absorption in hemoglobinopathies. Curr Mol Med 2008; 8: 646-662.
9. Erlandson ME, Walden B, Stern G, Hilgartner MW, Wehman J, Smith CH: Studies on congenital hemolytic syndromes, IV. Gastrointestinal absorption of iron. Blood 1962; 19: 359-378.
10. Olivieri NF: Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38: 57-62.
11. Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, Khan Y, Warley A, McCann FE, Hider RC, Frazer DM, Anderson GJ, Vulpe CD, Simpson RJ, McKie AT: Identification of an intestinal heme transporter. Cell 2005; 122: 789-801.
12. Lonnerdal B, Bryant A, Liu X, Theil EC: Iron absorption from soybean ferritin in nonanemic women. Am J Clin Nutr 2006; 83: 103-107.
13. Latunde-Dada GO, Van der Westhuizen J, Vulpe CD, Anderson GJ, Simpson RJ, McKie AT: Molecular and functional roles of duodenal cytochrome b (Dcytb) in iron metabolism. Blood Cells Mol Dis 2002; 29: 356-360.
14. Atanassova BD, Tzatchev KN: Ascorbic acid - important for iron metabolism. Folia Med (Plovdiv) 2008; 50: 11-16.
15. Mallory MA, Sthapanachai C, Kowdley KV: Iron overload related to excessive vitamin C intake. Ann Intern Med 2003; 139: 532-533.
16. Nienhuis AW: Vitamin C and iron. N Engl J Med 1981; 304: 170-171.
17. Kwiatkowski JL, Cohen AR: Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematol Oncol Clin North Am 2004; 18: 1355-1377, ix.
18. Picard V, Govoni G, Jabado N, Gros P: Nramp 2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other divalent cations into a calcein-accessible cytoplasmic pool. J Biol Chem 2000; 275: 35738-35745.
19. Andrews NC: Forging a field: the golden age of iron biology. Blood 2008; 112: 219-230.
20. Lee MG, Thirumalai CH, Terry SI, Serjeant GR: Endoscopic and gastric acid studies in homozygous sickle cell disease and upper abdominal pain. Gut 1989; 30: 569-572.
21. Ringelhann B, Konotey-Ahulu F, Dodu SR: Studies on iron metabolism in sickle cell anaemia, sickle cell haemoglobin C disease, and haemoglobin C disease using a large volume liquid scintillation counter. J Clin Pathol 1970; 23: 127-134.
22. Erlandson ME, Schulman I, Smith CH: Studies on congenital hemolytic syndromes. III. Rates of destruction and production of erythrocytes in sickle cell anemia. Pediatrics 1960; 25: 629-644.
23. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482-488.
24. Vichinsky E, Kleman K, Embury S, Lubin B: The diagnosis of iron deficiency anemia in sickle cell disease. Blood 1981; 58: 963-968.
25. Peterson CM, Graziano JH, de Ciutiis A, Grady RW, Cerami A, Worwood M, Jacobs A: Iron metabolism, sickle cell disease, and response to cyanate. Blood 1975; 46: 583-590.
26. Washington R, Boggs DR: Urinary iron in patients with sickle cell anemia. J Lab Clin Med 1975; 86: 17-23.
27. Kato GJ, McGowan V, Machado RF, Little JA, Taylor JT, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT: Lactate dehydrogenase as a biomarker of hemolysis- associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107: 2279-2285.
28. Sears DA, Anderson PR, Foy AL, Williams HL, Crosby WH: Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases. Blood 1966; 28: 708-725.
29. Schein A, Enriquez C, Coates TD, Wood JC: Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging 2008; 28: 698-704.
30. Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W: The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 2005; 184: 361-370.
31. Veuthey T, D'Anna MC, Roque ME: Role of the kidney in iron homeostasis: renal expression of prohepcidin, ferroportin, and DMT1 in anemic mice. Am J Physiol Renal Physiol 2008; 295:F1213-F1221.
32. Wareing M, Ferguson CJ, Delannoy M, Cox AG, McMahon RF, Green R, Riccardi D, Smith CP: Altered dietary iron intake is a strong modulator of renal DMT1 expression. Am J Physiol Renal Physiol 2003; 285:F1050-F1059.
33. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI: Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781.
34. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
35. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276.
36. Weiss G: Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790: 682-693.
37. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS: Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-1932.
38. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, Cunningham MJ: Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007; 48: 57-63.
39. Kroot JJ, Laarakkers CM, Kemna EH, Biemond BJ, Swinkels DW: Regulation of serum hepcidin levels in sickle cell disease. Haematologica 2009; 94: 885-887.
40. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E: Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92: 583-588.
41. Eckardt KU: Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease. Nephron 1994; 67: 7-23.
42. Nemeth E: Iron regulation and erythropoiesis. Curr Opin Hematol 2008; 15: 169-175.
43. Ago T, Sadoshima J: GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 2006; 98: 294-297.
44. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ: Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 2000; 20: 3742-3751.
45. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG: Growth differentiation factor-15/macrophage inhibitory cytokine- 1 induction after kidney and lung injury. Shock 2005; 23: 543-548.
46. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL: High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
47. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL: Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181-186.
48. Dullmann J, Wulfhekel U: Differences in the pattern of iron accumulation in primary and secondary hemochromatosis. Diagnostic importance and clinical consequences (in German). Folia Haematol Int Mag Klin Morphol Blutforsch 1990; 117: 413-417.
49. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, Sonnweber T, Eberwein L, Witcher DR, Murphy AT, Wroblewski VJ, Wurz E, Datz C, Weiss G: Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113: 5277-5286.
50. Oluboyede OA, Ajayi OA, Adeyokunnu AA: Iron studies in patients with sickle cell disease. Afr J Med Med Sci 1981; 10: 1-7.
51. Rao KR, Patel AR, Honig GR, Vida LN, Mc- Ginnis PR: Iron deficiency and sickle cell anemia. Arch Intern Med 1983; 143: 1030-1032.
52. O'Brien RT: Iron burden in sickle cell anemia. J Pediatr 1978; 92: 579-582.
53. Natta C, Creque L, Navarro C: Compartmentalization of iron in sickle cell anemia - an autopsy study. Am J Clin Pathol 1985; 83: 76-78.
54. Pippard MJ: Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78: 206-211.
55. Pippard MJ: Secondary iron overload; in Brock JH, Halliday JW, Pippard MJ (eds): Iron Metabolism in Health and Disease. London, Saunders, 1994, pp 272-300.
56. Rogers JT: Ferritin translation by interleukin- 1 and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood 1996; 87: 2525-2537.
57. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149.
58. Bargoma EM, Mitsuyoshi JK, Larkin SK, Styles LA, Kuypers FA, Test ST: Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome. Blood 2005; 105: 3384-3385.
59. Hagar W, Vichinsky EP, Theil EC: Liver ferritin subunit ratios in neonatal hemochromatosis. Pediatr Hematol Oncol 2003; 20: 229-235.
60. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999; 13: 273-279.
61. Hedo CC, Aken'ova YA, Okpala IE, Durojaiye AO, Salimonu LS: Acute phase reactants and severity of homozygous sickle cell disease. J Intern Med 1993; 233: 467-470.
62. Evans RW, Rafique R, Zarea A, Rapisarda C, Cammack R, Evans PJ, Porter JB, Hider RC: Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 2008; 13: 57-74.
63. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH: Role of l-type Ca 2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006; 84: 349-364.
64. Roudkenar MH, Halabian R, Oodi A, Roushandeh AM, Yaghmai P, Najar MR, Amirizadeh N, Shokrgozar MA: Upregulation of neutrophil gelatinase-associated lipocalin, NGAL/Lcn2, in beta-thalassemia patients. Arch Med Res 2008; 39: 402-407.
65. Toivanen A, Ihanus E, Mattila M, Lutz HU, Gahmberg CG: Importance of molecular studies on major blood groups - intercellular adhesion molecule-4, a blood group antigen involved in multiple cellular interactions. Biochim Biophys Acta 2008; 1780: 456-466.
66. Kuypers FA, Yuan J, Lewis RA, Snyder LM, Kiefer CR, Bunyaratvej A, Fucharoen S, Ma L, Styles L, de Jong K, Schrier SL: Membrane phospholipid asymmetry in human thalassemia. Blood 1998; 91: 3044-3051.
67. Haynes J Jr, Obiako B, King JA, Hester RB, Ofori-Acquah S: Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine- exposed sickle red blood cells. Am J Physiol Heart Circ Physiol 2006; 291:H1679-H1685.
68. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM: Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 2006; 116: 808-816.
69. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M: Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 2005; 102: 1324-1328.
70. Wang X, Garrick MD, Yang F, Dailey LA, Piantadosi CA, Ghio AJ: TNF, IFN-gamma, and endotoxin increase expression of DMT1 in bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 289:L24-L33.
71. Quigley JG, Yang Z, Worthington MT, Phillips JD, Sabo KM, Sabath DE, Berg CL, Sassa S, Wood BL, Abkowitz JL: Identification of a human heme exporter that is essential for erythropoiesis. Cell 2004; 118: 757-766.
72. Keel SB, Doty RT, Yang Z, Quigley JG, Chen J, Knoblaugh S, Kingsley PD, De Domenico I, Vaughn MB, Kaplan J, Palis J, Abkowitz JL: A heme export protein is required for red blood cell differentiation and iron homeostasis. Science 2008; 319: 825-828.
73. Fillet G, Beguin Y, Baldelli L: Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844-851.
74. Ludwiczek S, Aigner E, Theurl I, Weiss G: Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101: 4148-4154.
75. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin- 1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102: 1906-1910.
76. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, Zoller H, Bellmann-Weiler R, Niederegger H, Talasz H, Weiss G: Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008; 111: 2392-2399.
77. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T: Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007; 110: 2182-2189.
78. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463. (Pubitemid 36857598)
79. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G: The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006; 91: 809-812.
80. Wang WC, Morales KH, Scher CD, Styles L, Olivieri N, Adams R, Brambilla D: Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr 2005; 147: 244-247.
81. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D: Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126: 896-899.
82. Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, Taher A: Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with betathalassaemia. Eur J Haematol 2009; 82: 454-457.
83. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T: A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-508.
84. Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coic L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF: Patient- reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 2008; 119: 133-141.
85. Herrick JB: Peculiar elongated and sickleshaped red blood corpuscle in a case of severe anemia. Arch Intern Med 1910;5:517-521.
86. Pauling L, Itano HA, Singer SJ, Wells IC: Sickle cell anemia, a molecular disease. Science 1949;110:543-548.
87. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D: Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.